Verve Therapeutics, Inc. (NASDAQ:VERV) Receives $25.75 Average PT from Brokerages

Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) have been assigned a consensus rating of “Buy” from the six brokerages that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month price target among brokerages that have covered the stock in the last year is $25.75.

A number of research analysts have commented on the stock. Canaccord Genuity Group increased their price target on shares of Verve Therapeutics from $32.00 to $39.00 and gave the company a “buy” rating in a research report on Tuesday, April 15th. Royal Bank of Canada decreased their target price on shares of Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 4th. Guggenheim raised their price objective on Verve Therapeutics from $18.00 to $24.00 and gave the company a “buy” rating in a research note on Tuesday, April 15th. William Blair reissued an “outperform” rating on shares of Verve Therapeutics in a research note on Friday, February 21st. Finally, HC Wainwright raised their price target on Verve Therapeutics from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Monday, April 14th.

Verve Therapeutics Stock Performance

Shares of VERV stock opened at $4.78 on Friday. Verve Therapeutics has a 52-week low of $2.86 and a 52-week high of $9.31. The business’s fifty day moving average is $5.57 and its 200 day moving average is $5.92. The company has a market capitalization of $424.44 million, a PE ratio of -1.94 and a beta of 1.86.

Verve Therapeutics (NASDAQ:VERV) last released its earnings results on Thursday, February 27th. The company reported ($0.58) EPS for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.14. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. The business had revenue of $13.08 million for the quarter, compared to analysts’ expectations of $3.94 million. On average, sell-side analysts forecast that Verve Therapeutics will post -2.49 EPS for the current fiscal year.

Institutional Investors Weigh In On Verve Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. GAMMA Investing LLC lifted its holdings in Verve Therapeutics by 189.7% in the fourth quarter. GAMMA Investing LLC now owns 6,054 shares of the company’s stock worth $34,000 after buying an additional 3,964 shares during the period. KFG Wealth Management LLC bought a new position in shares of Verve Therapeutics in the 1st quarter worth approximately $46,000. IFP Advisors Inc lifted its stake in shares of Verve Therapeutics by 823,700.0% in the 4th quarter. IFP Advisors Inc now owns 8,238 shares of the company’s stock valued at $47,000 after purchasing an additional 8,237 shares during the period. BNP Paribas Financial Markets bought a new stake in shares of Verve Therapeutics during the fourth quarter valued at approximately $50,000. Finally, Impact Partnership Wealth LLC purchased a new stake in Verve Therapeutics in the fourth quarter worth $70,000. Hedge funds and other institutional investors own 97.11% of the company’s stock.

About Verve Therapeutics

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.